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Background
There are limited prospective, prognostic data for cardi-
ovascular magnetic resonance (CMR) in the same
patients with suspected coronary heart disease (CHD).
CE-MARC established the diagnostic performance of
CMR (and SPECT), with a predefined objective to deter-
mine both modalities’ ability to predict major adverse
cardiovascular events (MACE).
Methods
All CE-MARC patients underwent annual follow-up for 3
years to assess the occurrence of MACE (cardiovascular
death, acute coronary syndrome, unscheduled revasculari-
zation or hospital admission for any cardiovascular cause).
Time to MACE was assessed by univariate (log-rank test)
and multivariate (Cox proportional hazards regression)
analysis after adjustment for major cardiovascular risk fac-
tors. Net reclassification improvement (NRI) and discrimi-
nation (IDI) of the risk of MACE with CMR, incremental
to standard clinical risk factors was calculated.
Results
747(99.3%) of 752 patients recruited had complete
follow-up. Of 633 who underwent both CMR and
SPECT, 41(6.5%) had at least 1 MACE event. Abnormal
CMR (HR 2.51; 95%CI, 1.32-4.79; p = 0.005) findings
were strong and independent predictors of MACE
(Figure 1). CMR also showed improved reclassification
and risk stratification (Net Reclassification Index, NRI
0.57(95%CI 0.26-0.89); Integrated Discrimination
Improvement, IDI 0.02 (95%CI 0.002-0.06)).
Conclusions
Three-year follow-up of the CE-MARC trial population
demonstrates that abnormal CMR findings are
independent predictors of MACE, and can reclassify patient
risk beyond the standard major cardiovascular risk factors.
This further supports the role of CMR for the assessment
and management of patients with suspected CHD.
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Figure 1 Kaplan-Meier event curves for CMR for MACE.
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